logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF,  et al.
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Journal Article
|
Review

Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective

Guglielmetti L, Chiesi S, Eimer J, Dominguez J, Masini T,  et al.
2020-07-23 • Future Microbiology
2020-07-23 • Future Microbiology
Drug-resistant tuberculosis (TB) represents a substantial threat to the global efforts to control this disease. After decades of stagnation, the treatment of drug-resistant TB is undergo...
Journal Article
|
Research

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

Mbuagbaw L, Guglielmetti L, Hewison CCH, Bakare N, Bastard M,  et al.
2019-05-01 • Emerging Infectious Diseases
2019-05-01 • Emerging Infectious Diseases
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 c...
Journal Article
|
Research

Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries

Guglielmetti L, Hewison CCH, Avaliani Z, Hughes AJ, Kiria N,  et al.
2017-02-01 • International Journal of Tuberculosis and Lung Disease
2017-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of i...